Drug intelligence / Profile preview

AUTO9

Development stage: Preclinical
Lead developer: Autolus Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AUTO9 is an experimental immunotherapy drug designed as a chimeric antigen receptor (CAR) T cell therapy targeting multiple antigens, specifically CD123, CD33, and CLL-1. It was initially developed by University College London. The drug is intended for the treatment of hematological malignancies such as acute myeloid leukemia (AML). Its mechanism of action involves genetically engineering a patient's own T cells to express CARs that recognize and bind to the target antigens on cancer cells, leading to targeted immune-mediated destruction of those malignant cells[1].

Targets

CLEC12AIL3RA (Interleukin 3 Receptor)CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on AUTO9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUTO9.

Explore the full profile